WebAchieving Digital Enlightenment in 2024 and Beyond. As evolving technologies and societal changes continue to push the use of digital channels and media, the reality is that healthcare professionals, patients and other key stakeholders are increasingly ‘digital natives’, who expect new ways of interacting. WebJan 26, 2024 · Double Bond Pharmaceutical International AB, headed up by CEO Igor Lokot, is developing drugs for cancers, infections, autoimmune diseases and other life-threatening disorders. As Lokot explained to BioPharma Dive in an interview, its model is to take existing drugs and repurpose them. "We want to take approved drugs and make …
APMnews - L
WebNov 22, 2024 · PARIS, 20 mars 2024 (APMnews) - Le Conseil national de l'ordre des pharmaciens (Cnop) a confirmé vendredi à APMnews avoir assigné en référé la société de livraison de médicaments Livmed's, sans en préciser le motif, confirmant des informations dévoilées par le président de l'Union syndicale des pharmaciens d'officines (Uspo ... WebThe company Double Bond Pharmaceutical and the drug SI-053. Double Bond Pharmaceutical is a Swedish biotechnology company that specializes in the development of innovative therapies for cancer and other diseases. The company was founded in 2010 and is headquartered in Uppsala, Sweden. iron cross templar
Bond Biosciences Therapeutics for Ion-Related Diseases
WebBiond intends to use the proceeds to move its lead drug candidate, BION-202, into clinical trials ... developing innovative drugs and establishing collaborations with leading pharma companies. 2 Biond’s in-house pipeline is based on internal research of newly discovered immune-checkpoints WebJan 8, 2024 · Biond aims to translate high quality science into therapies for diseases with unmet medical needs by developing innovative drugs and establishing collaborations … WebMar 31, 2024 · Convertible bonds. In July 2024, Basilea issued CHF 97.085 million convertible bonds due 2027 ("New Bonds", ISIN: CH0554992062; SSN: 55'499'206) and repurchased CHF 47.085 million of its CHF 200 million existing convertible bonds due 2024 ("Existing Bonds", ISIN: CH0305398148; SSN: 30'539'814). Through these transactions, … iron cross temporary tattoo